

mTORC1 activation in presumed classical monocytes: observed correlation with human size variation and neuropsychiatric disease

Karl Berner¹, Naci Oz^{2,3}, Alaattin Kaya², Animesh Acharjee^{4,5,6}, Jon Berner¹

¹Woodinville Psychiatric Associates, Woodinville, WA, USA

²Department of Biology, Virginia Commonwealth University, Richmond, VA, USA

³Life Sciences, Virginia Commonwealth University, Richmond, VA, USA

⁴Institute of Cancer and Genomics Sciences, University of Birmingham, Birmingham, UK

⁵Institute of Translational Medicine, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK

⁶MRC Health Data Research UK (HDR UK), London, UK

Correspondence to: Jon Berner; email: jonbernermd@gmail.com, <https://orcid.org/0000-0003-3117-6482>

Keywords: ketamine, lithium, monocyte, mTORC1, rapamycin

Received: December 19, 2023 **Accepted:** July 5, 2024

Published: July 26, 2024

Copyright: © 2024 Berner et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Gain of function disturbances in nutrient sensing are likely the largest component in human age-related disease. Mammalian target of rapamycin complex 1 (mTORC1) activity affects health span and longevity. The drugs ketamine and rapamycin are effective against chronic pain and depression, and both affect mTORC1 activity. Our objective was to measure phosphorylated p70S6K, a marker for mTORC1 activity, in individuals with psychiatric disease to determine whether phosphorylated p70S6K could predict medication response.

Methods: Twenty-seven females provided blood samples in which p70S6K and phosphorylated p70S6K were analyzed. Chart review gathered biometric measurements, clinical phenotypes, and medication response. Questionnaires assessed anxiety, depression, autism traits, and mitochondrial dysfunction, to determine neuropsychiatric disease profiles. Univariate and multivariate statistical analyses were used to identify predictors of medication response.

Results: mTORC1 activity correlated highly with both classical biometrics (height, macrocephaly, pupil distance) and specific neuropsychiatric disease profiles (anxiety and autism). Across all cases, phosphorylated p70S6K was the best predictor for ketamine response, and also the best predictor for rapamycin response in a single instance.

Conclusions: The data illustrate the importance of mTORC1 activity in both observable body structure and medication response. This report suggests that a simple assay may allow cost-effective prediction of medication response.

INTRODUCTION

Although formal biochemical analysis of aging pathways is a relatively novel academic discipline, medical modulation of nutrient sensing pathways in humans has been widespread since the approval of lithium in the United States in 1970. Lithium, a glycogen synthase kinase inhibitor, has proven efficacy

not only in bipolar disorders [1] but also more recently in Alzheimer's disease prophylaxis [2], and is known to extend *Drosophila* lifespan [3]. The combination of lithium with drugs that inhibit the mammalian target of rapamycin complex 1 (mTORC1) (by rapamycin) and mitogen-activated protein kinase (by trametinib) pathways, can, in *Drosophila*, increase lithium's 11% lifespan extension to 48% [4].

The inexpensive generic drugs ketamine and rapamycin, that are efficacious in both chronic pain and depression [5, 6], modulate different nutrient sensing pathways. These medications have proximal impacts on the innate nitrogen sensing pathway in every cell in the body via mTORC1, although potentially in opposing directions. Ketamine blocks an extracellular glutamate sensor, the N-methyl-D-aspartate (NMDA) receptor, which is preferentially activated during high activity in nerve cells. The resulting decrease in voltage-gated calcium flux and mTORC2 downregulation may stabilize small G protein Rheb and activate mTORC1 [7, 8]. In contrast, rapamycin mimics amino acid restriction and subsequently downregulates glycolytic-dependent growth and inflammatory processes, resulting in mTORC1 inhibition [4].

Optimal population use of these inexpensive medications in patients requires identification of biomarkers which specify the dose requirements for each drug in each individual. Absent aggressive innovation in diagnostic technology, it is likely the prophylactic effects of lithium, ketamine, or rapamycin will be introduced into the community too late to protect hundreds of millions of individuals who will ultimately die from Alzheimer's disease or widespread behavioral consequences of depression. An additional barrier is minimal commercial financial interest to address "the last mile problem," educating the individual patient to take generic stigmatized medications lifelong with potential immediate side effect versus uncertain long-term benefit.

Treatment-resistant psychiatric patients, refractory to standard Food and Drug Administration (FDA) approved medications for depression, in contrast, actively demand novel treatments and diagnostics. Although high dimensional tissue assays, both genomic and metabolomic, are recently commercially available, in our experience, practical utility is limited by cost, convenience, excessive dimensionality of multiple findings, and uncertain applicability of observed peripheral somatic tissue pathophysiology to brain pathophysiology.

In response to patients' unmet needs, we observed that recent developments in Western blot technology and conceptual advances in biochemical pathways derived from yeast models potentially allow for cost-effective estimation of mTORC1 activity in the individual patient.

We hypothesized that biochemical activity in activated monocytes is a cost-effective estimate of baseline human mTORC1 gain of function. The cost (\$45) and convenience of the acquisition of blood cells is trivial. Although blood is composed of a heterogeneous group

of cells, from a biochemical perspective most cells in the blood have minimal mTORC1 activity [9]. The exception to this generalization may be monocytes; in mice models phosphorylation of p70 ribosomal S6 kinase (p70S6K), a downstream target of mTORC1, was found to be uniquely elevated in monocytes relative to neutrophil or lymphocyte subsets [9]. In physiological settings, Ly6hi "classical monocytes" with elevated Ki67+activity transition into terminally differentiated Ly6low tissue-resident monocytes during exposure to colony stimulating factor 1 (CSF-1) from damaged portions of the vascular endothelium [10, 11]. Pathological overgrowth of these transitioning cells may be observed in numerous varied disease phenotypes: systemic juvenile idiopathic arthritis [9], lithium-responsive bipolar disorder [1], and rapamycin treatment in amyotrophic lateral sclerosis [12]. Unfortunately, blood samples may be less than optimal as markedly higher expression of PI3K-AKT, glycolytic genes, and Hif1 α are observed in wound "M1-like" macrophages at day 2 post injury compared with blood monocytes [13].

The objective of this study was to determine whether presumed macrophage mTORC1 activity, as measured by p70S6K phosphorylation, has implications in terms of identifying undiscovered patient phenotypes or indications for specific medications.

RESULTS

Clinical variables of the patients

Twenty-five patients and two first-degree relatives of patients were recruited for this study. Descriptive statistics of their clinical variables and scores on the questionnaires can be found in Table 1. The central tendency in this sample is consistent with membership in a community fee-for-service psychiatric clinic. The women are middle-aged, overweight, and with a normative height. They have a moderate degree of residual anxiety as inferred from the GAD-7. They score in the mid-range for autism traits on the AQ-10. The scores on the PHQ-9, an estimate of cognitive fatigue associated with fibromyalgia, are skewed towards substantial clinical disease. Based on these results, these patients are not normal, and not representative of a random community sample.

Expression and phosphorylation of p70S6K

Phosphorylation of p70S6K, a downstream target of mTORC1, was measured as a proxy for mTORC1 activation in monocytes. The Western blot results are shown in Supplementary Figure 1. During analysis, difficulty in actin estimation occurred in 10 samples,

Table 1. Summary statistics of the clinical features with percentiles.

Clinical variable	Mean	SD	Minimum	25 th percentile	75 th percentile	Maximum
Ketamine Response	0.31	0.47	0	0	1	1
Age	47	13	21	36	55	69
Height in cm	167.6	7.6	152.4	160.0	172.7	177.8
Weight in kg	77.1	17.2	39.5	65.3	90.7	110.2
BMI	28	6.4	16	23	32	43
Head circumference in cm	55.9	1.7	50.8	55.9	55.9	58.4
Head circumference/BMI ratio	0.83	0.2	0.53	0.71	0.98	1.3
Waist circumference in cm	99.1	15.0	78.7	86.4	109.2	149.9
Waist circumference/Height ratio	0.57	0.15	0	0.49	0.66	0.83
Pupil distance in mm	65	3.5	58	62	67	72
GAD-7 score	14	5.5	2	8.5	18	21
AQ-10 score	5.1	2.4	0	3	7	9
KSP-6 score	19	4.4	3	17	22	24

AQ-10, 10-item Autism Spectrum Quotient; BMI, body mass index; GAD-7, 7-item Generalized Anxiety Disorder; KSP-6, Karolinska Scales of Personality; SD, standard deviation.

limiting actin as a single control for variable aliquot sizing to 17 patients. However, the relative ratio of phosphorylated and unphosphorylated p70S6K could still be determined for all 27 samples (Table 2). Descriptive statistics of expression and phosphorylation of p70S6K of the samples are presented in Table 3.

Clusters were identified based on multivariate analysis

Even within a highly selected population, women with anxiety and fibromyalgia, at most representative of 1-2% of the population, there was substantial within-group variability [14]. This within-group variability is the bane of clinical management of syndromic disease. Accordingly, we attempted to identify phenotype clusters potentially allowing for more targeted treatments.

Visual inspection of the correlation heatmap matrix (Figure 1) identified a few clusters. For example: One cluster was defined by the “antidiabetic” bobble-head frame (large head circumference relative to BMI), low p70S6K expression, and anxiety. Another cluster was defined by p70S6K expression, head circumference, and pupil distance.

Principal component analysis identified two clusters

We also used another method of data compression, namely principal component analysis (PCA). PCA is extremely valuable as it allows for the identification of nearest neighbors defined by multiple variables rather than with a binary disease identification. PCA identified two principal components (PCs) accounting

for more than 50% of the variance in a sample of 8 biometric variables and neuropsychiatric disease profiles (anxiety and autism) based on the GAD-7, KSP-6, and AQ-10 scores (Supplementary Figure 2). PC1 explained 36.5% and PC2 explained 18% variance, respectively.

Phosphorylated p70S6K was the best predictor for ketamine response

We used ketamine response as an outcome variable (responded as “1” vs. not responded as “0”) and used the Random Forest method (as classification mode) to identify key clinical parameters that predict ketamine response. Random forest ranking using mean decrease in accuracy identified phosphorylated p70S6K, height, and ratio of head circumference/BMI as the top three predictive features (Figure 2). A list of all the parameters with their ranking based on Random Forest model can be found in Supplementary Table 2.

We also performed univariate t-tests to estimate the parameters’ area under curve (AUC). A list of the AUCs can be found in Supplementary Table 1. The highest AUC was found for phosphorylated p70S6K (AUC 0.79), indicating this is a good predictor of ketamine response, and the lowest AUC was found for p70S6K expression (AUC 0.51) (Figure 3).

Rapamycin response correlated with phosphorylated p70S6K: case example

A 30-year-old male patient has a chronic history of ulcerative colitis and idiopathic pancreatitis. At index

Table 2. Western blot results of mTORC1 activity per sample.

Sample	p70S6K	Actin	Phosphorylated p70S6K	Phosphorylated p70S6K/total p70S6K ratio
Sample 2	702	NA	4789	6.8
Sample 3	7748	7285	3888	0.5
Sample 4	458	NA	5518	12.0
Sample 5	1319	NA	5513	4.2
Sample 6	966	NA	7211	7.5
Sample 8	1018	9114	6487	6.4
Sample 9	5425	NA	9938	1.8
Sample 10	7311	NA	12776	1.7
Sample 14	7538	7285	5411	0.7
Sample 16	7540	8094	10632	1.4
Sample 17	4706	9003	938	0.2
Sample 18	5707	6254	1116	0.2
Sample 19	4467	6174	1224	0.3
Sample 21	8354	7427	4310	0.5
Sample 22	2748	NA	4817	1.8
Sample 23	4362	8303	2462	0.6
Sample 25	1055	10376	8766	6.4
Sample 27	883	8257	2526	2.9
Sample 28	297	7612	5579	18.8
Sample 29	5483	NA	10944	2.0
Sample 31	1591	4441	10877	6.8
Sample 32	6768	4529	3252	0.5
Sample 33	979	8307	6648	6.8
Sample 35	5269	7184	549	0.1
Sample 36	426	8186	7230	17.0
Sample 37	284	NA	6881	24.2
Sample 38	2220	NA	10547	4.8

NA, not available.

Table 3. Overall mTORC1 activity.

mTORC1 activity	Mean	SD	Minimum	25 th percentile	75 th percentile	Maximum
Total p70S6K	0.58	0.45	0.039	0.11	0.91	1.5
Phosphorylated p70S6K	0.67	0.57	0.076	0.3	0.8	2.4
Phosphorylated p70S6K/total p70S6K ratio	5.3	6.4	0.1	0.53	6.8	24

p70S6K, p70 ribosomal S6 kinase; SD, standard deviation.

presentation, he was occupationally disabled with crippling fatigue, intermittent hospitalizations for intractable vomiting and pain, and severe cognitive impairment. Psychostimulant use was palliative in contrast to previous antidepressants and standard immunosuppressive agents. In the course of standard clinical discussion regarding the use of rapamycin in treatment-resistant lupus and subsequent Treg induction, his mother volunteered to provide a tissue sample consistent with known heritability of autoimmunity.

Subsequent evaluation revealed the largest amount of phosphorylated p70S6K in this clinical sample, suggesting elevated Bayesian probability for rapamycin indication. The patient consented to a 1 mg daily rapamycin trial under Washington State Right-to-Try statutes with a first-degree relative present (See Informed Consent Form in Supplemental Data). After a four-week trial, the patient reported complete cessation of fatigue with an exercise tolerance of 12 hours, spontaneous cessation of lifelong 1.5 pack daily nicotine dependence

with one week, and minimal self-imposed dietary restriction associated with residual disease (1/30 days).

Patient statement: “After continued use of rapamycin, I have found several noticeable changes in my emotional and physical states. My dependency on nicotine is no longer existent and I have fully quit without implementing any secondary forms of cessation. My severe ulcerative colitis, Crohn’s, and pancreatitis flare-ups have become increasingly rare. On the off chance they do happen, my recovery time is incredibly

fast. I have been able to go from a very restrictive diet to prevent them to now being able to have a much more varied and tolerable diet. My energy levels have become extremely high and I am able to work as long and hard at whatever task I’m working on. This includes minimal fatigue and recovery time afterwards as well. Lastly, my overall mental health has become very much improved. My depression has become very minimal with very few bad days. I’ve been much happier to the point where I have actively started creating a social life. I haven’t had the desire, energy, or positivity to do this in several years”.




Figure 1. Heatmap visualization based on spearman rank correlation and hierarchical clustering. The legend bar shows positive (red) or negative (green) correlations between the various parameters.

DISCUSSION

Our data suggest that human variability of mTORC1 gain of function observed during the differentiation of stem-like monocytes into vascular tissue-resident macrophages correlates with physical size, subsets of neuropsychiatric disease, and clinical ketamine or rapamycin response.

The major strength of this study is the absence of commercial interests. Funding for this study ultimately derived from patients with treatment-refractory disease with a potentially life-threatening course. All medications of interest studied were generic, historically underutilized, and relevant to their probable benefit absent commercial marketing. No professional conflicts of interest regarding patents, pending grant applications, or publication prominence required for professional advancement were present. In the absence of commercial conflicts and subsequent

required regulatory delays, the latency between project design and successful clinical application was short, six months. This latency is entirely consistent with the intent of recent regulatory developments in Federal and Washington state Right-to-Try laws [15].

This study has several limitations. First, this study involved only female patients and cannot be extrapolated to males. So, a study in a male cohort is required given elevated bimodal expression of synaptic disease in males (overgrowth in autism vs. undergrowth in schizophrenia) [16, 17], decreased relative risk of hyperinflammatory manifestations (somatic autoimmune disease and central nervous system mood disorders) [18], and the highly variable differences in response to life-extending interventions between sexes, such as reduced IGF-1 or mTOR signaling, observed in mice [19]. Second, to confirm the proposed tentative model, isolation of monocyte subpopulations from the blood using cell sorting is needed. Third, non-linear




Figure 2. Rank of the clinical features that affect ketamine response based on the random forest algorithm. Ketamine response is indicated as “1” for responded and “0” for not responded. Corresponding up- and downregulation of the parameters are indicated on the right side of the plot. AQ10, 10-item Autism Spectrum Quotient; BMI, body mass index; GAD7, 7-item Generalized Anxiety Disorder; KSP6, HC, head circumference; HC BMI, ratio head circumference/BMI ratio; Karolinska Scales of Personality; PCA, principal component analysis; Pupil Dist, pupil distance; P.P70, phosphorylated p70S6K; P.P70.P70, ratio of phosphorylated p70S6K/total p70S6K; WC, waist circumference; WC Height, ratio waist circumference/height.

distributions of mTORC1 activity require further investigations using alternative readouts e.g., 4E-binding protein 1 (4EBP1) or AKT subtypes, which might allow for a more robust biochemical gradient when estimating medication selection and dose. Fourth, the results of multiple non-preregistered statistical comparisons within a restricted clinical sample require confirmation in a study with a larger number of patients before applying the observed effect sizes to broader populations. Fifth, absent randomized assignment of patients to treatment and control groups, it cannot be ruled out that there is a confounding selection bias for ketamine-maintained patients to be more predisposed to trying novel therapies. A larger, randomized trial will be required to confirm our results.

The strong association between a fixed physical structure (i.e., head size and pupil distance) and dynamic macrophage differentiation is consistent with known mTORC1 effects on macrocephaly [20]. This finding provides face validity to the concept that

systemic mTORC1 gain of function can be estimated easily, albeit incompletely, with simple physical measurements and crude blood analysis. Age, exercise, and diet-related hypertrophic lipodystrophy manifest as increased waist circumference and BMI and may rely on different proximal upstream activators of mTORC1 activated later in development than in infancy and adolescence.

The miscellaneous associations between multiple neuropsychiatric syndromes (anxiety and autism) and mTORC1 activity in blood monocytes direct attention to the structural role of tissue-resident macrophages in the brain, the microglia. In the brain, are physical tension and psychological tension the same? The brain is a closed space due to the inflexibility of the skull. All learning is a zero-sum game. Therefore, an augmented synaptic trace associated with a new experience requires the corresponding phagocytosis of a less preferred synapse. The extracellular matrix, in turn, must be digested to avoid “tension” as different




Figure 3. Phosphorylated p70S6K best predicted ketamine response. The phosphorylated p70S6K marker had an AUC of 0.80 (confidence interval: 0.54-0.97) for predicting ketamine response. An optimal cutoff is shown (indicated by the red dot) based on true positive and false positive rate.

synaptic “eigenvalues” embedded in brain activity “eigenvector” grow in size with time and distort the morphology of connecting tissue or present risk of local excitotoxicity [21]. This conceptual framework suggests that different densities of the extracellular matrix and embedded synaptic structure may manifest as dimensional behavioral traits in humans.

The association of mTORC1 activity with ketamine response is consistent with the literature. Reductions in serum TNF- α were found to correlate with clinical antidepressant response after intravenous ketamine treatment; these changes were observed within 40 minutes [22]. Recent work in invasive vs. non-invasive ovarian cancer revealed that high levels of tumor-derived N-acetyl aspartate competitively inhibited the NMDA receptor on M1 tissue-resident macrophages and induced M2 polarization [23]. The resultant biochemical profile within the proliferative MKI67+ M2 macrophage (GLS1 upregulation, SLCA5/SLCA7 upregulation) strongly corresponded to the biochemical phenotype observed in the whole blood, inferred monocyte fraction, in human lithium responders [1]. These converging observations suggested the possibility that the M2 homeostatic microglia population (CD163+) in the brain of depressed patients is of inadequate size to allow for adequate synaptic pruning or trophic support [8]. The upregulation of BCL-2 in lithium responders [1] could potentially suggest protection against premature senescence of the long-lived microglia stem cell population, which migrates into the brain from the yolk sac at week 4 of embryonic development.

The association of mTORC1 activity with rapamycin response is consistent with the literature, specifically rapamycin’s efficacy in treating tuberous sclerosis [24]. Rapamycin also has documented efficacy in a host of polygenetic autoimmune disorders, specifically in the prototype disorder lupus [25] and the case-specific disorder ulcerative colitis [26]. Its proximal mechanism of action may relate to biasing differentiation of naive T-cells towards the FoxP3+ T-regulatory and CD8+ CD45RO+ memory subtypes dependent on fatty acid oxidation and reducing interleukin (IL)-4 and IL-17 production by CD3+CD4-CD8- double negative T-cells.

The observed disjunction between relative phosphorylated p70S6K and absolute p70S6K abundance correlations with clinical phenotypes suggested careful attention to the different physiological drivers of metabolic reprogramming in macrophages. The total amount of available p70S6K and its active phosphorylated form may only partially control macrophage activity. Note that phosphoinositide 3-kinase (PI3K)- γ inhibition alone promoted the “M1-phenotype (IL-12 excretion)”

relative to the “M2-phenotype (IL-10 excretion)” in the context of lipopolysaccharide (LPS) stimulation without affecting p70S6K activity [27]. Even within the “M2-phenotype” in cultured microglial cells, PI3K/TORC1 independent (IL-4) and dependent (ATP/purine) extracellular receptor activation pathways appeared to be present [28].

In conclusion, recent conceptual, technological, and regulatory developments may allow for the rapid development of a simple blood assay supporting both widespread and yet targeted use of generic medications known to extend both healthspan and lifespan. This blood assay attempts to capture a snapshot of “stem-like” monocytes that will transform into tissue-resident macrophages. The resulting image of innate mTORC1 and mTORC2 activation may provide insights into the management of neuropsychiatric disease. The current study provides a proof of concept that requires replication in larger cohorts and using isolated monocyte subpopulations.

MATERIALS AND METHODS

Patients and samples

Patients or first-degree relatives of patients with treatment-refractory disease were recruited from a community fee-for-service psychiatric practice in the course of chronic medication and case management between January and March of 2023. Patient selection was informal, largely in the background of discussions of synaptic undergrowth and overgrowth syndrome associated with autism/pain/mood disorders or modulation of aging-related biochemical pathways. Enrollment was entirely driven by patient interest, absent available pilot data suggesting immediate efficacy or application. A small sample size ($n = 20\text{--}40$) was chosen as it produces effect sizes of clinical relevance and can be more economically replicated by other research groups. Only females were investigated as their gender is greatly enriched for phenotypes of interest (anxiety, depression, and neurogenic pain), which allows for both more rapid recruitment and subsequent application of possible findings in a larger population.

We assessed height, weight, head circumference, pupil distance, current medication, and age. Self-administered questionnaires were used to assess the presence of various disorders. Depression was assessed with the 9-item Patient Health Questionnaire (PHQ-9) [29], anxiety with the 7-item Generalized Anxiety Disorder (GAD-7) questionnaire [30], presence of autism traits with the 10-item Autism Spectrum Quotient (AQ-10) questionnaire [31], and mitochondrial dysfunction

was assessed with the 6-item Karolinska Scales of Personality (KSP-6) questionnaire [32]. Retrospective chart review identified individuals who had or were receiving benefit from self-administered ketamine or rapamycin therapy; response was scored as “1” for responded and “0” for not responded. The response amplitude was not estimated; patient sustained use was taken as a marker of efficacy.

Fasting blood samples were collected in EDTA tubes between 8 AM and 12 PM within 2 weeks of clinical evaluation. Blood samples were centrifuged for 30 minutes at 15,000 rpm and an aliquot of cells was visually extracted. The samples were frozen on dry ice immediately for later examination.

Informed consent

The retrospective case review was exempt from Institutional Review Board approval under Category 2 of the Basic Health and Human Services Policy for Protection of Human Research Subjects Subpart A Section 46.101 [33]. All participants signed informed consent forms (see Supplementary Data) consistent with Washington State Right-to-Try statutes Chapter 69.77 RCW [15]. Elements of the Right-to-Try statutes include acknowledgment of life-threatening disease in the patient or relative, absence of available investigational treatments or diagnostics, and assumption of personal financial responsibility for proposed interventions.

Western blot analysis

To examine the expression and phosphorylation of p70S6 kinase in each sample, Western blot analysis was carried out. To extract the proteins, 5 µl of each cell sample was mixed with 300 µl radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% TritonX-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM ethylenediaminetetraacetic acid (EDTA), 5% glycerol, 1% 100 X Protease Inhibitor Cocktail) and kept on ice for 30 min. Samples were homogenized with a Branson SFX150 Ultrasonic Cell Disruptor (Emerson, UK) at amplitude setting: 40%; sonication pulse rate: 10 seconds ON, 10 seconds OFF, for 30 seconds on ice. Homogenized samples were kept on ice for 15 minutes and then centrifuged at 13,000 rpm for 15 min at 4° C. The supernatants containing the soluble protein were collected and transferred to new tubes. Proteins were separated on 10% Bis-Tris SDS gel. After transferring the proteins from the gel to a polyvinylidene difluoride membrane, subsequent treatments (blocking, antibody treatment) were performed using 5% bovine serum albumin (BSA) solution prepared in 1X Tris-buffered Saline, 0.1% Tween20. Antibodies against

non-phosphorylated p70 S6 kinase (Cell Signaling Technology, USA, catalog no: 2708), or phosphorylated p70 S6 kinase (Cell Signaling Technology, catalog no: 9234) were used, as well as against actin (Thermo Fisher Scientific, USA, catalog no: MA1-744) as an internal (protein loading) control. Antibody dilutions were prepared according to the manufacturer's protocol.

Analysis of Western blot results for measuring mTORC1 activity

Relative optical densities of target proteins were measured with ImageJ (Version 1.53t) software, and normalized to those of β-actin, when available. The β-actin bands for some samples were oversaturated during imaging, so these were instead normalized as a ratio of P-p70S6K/p70S6K.

Visual inspection of raw data revealed non-Gaussian distribution and/or outliers in many variables, suggesting Spearman correlation analysis. All clinical variables were then examined in a correlation matrix without preregistered hypothesis testing.

Univariate and multivariate statistical analysis

Spearman correlation or association analysis was performed to understand the linking of the multiple clinical parameters. A univariate t-test was performed for ketamine response as outcome variable. P-value <0.05 was considered for statistical significance.

Principal component analysis (PCA) was used to decrease the dimensionality of a given dataset while retaining the utmost significant information. This was achieved through the identification of a novel collection of variables, referred to as the principal components (PCs), which exhibit no correlation and effectively capture the highest amount of variance present in the dataset. A total of 21 missing values in the features were detected in the twenty-seven patients. The missing values were imputed using median values, and the data were normalized using auto scaled (Z-transformation).

We have used R (<https://www.r-project.org/>) and metaboanalyst (<https://www.metaboanalyst.ca/>) tools for data analysis.

Random forest analysis, a type of ensemble supervised machine learning, was used to make the results more stable by combining the predictions of several decision trees [34, 35]. Random forest analysis was used for both classification and regression. We ranked (in decreasing order) the features based on mean decrease in accuracy.

Consent

All participants gave informed consent for the study by signing an informed consent form.

Abbreviations

AUC: Area under the curve; AQ-10: 10-item Autism Spectrum Quotient; BMI: Body mass index; BSA: Bovine serum albumin; CI: Confidence interval; EDTA: Ethylenediaminetetraacetic acid; FDA: Food and drug administration; GAD-7: 7-item Generalized Anxiety Disorder; IL: Interleukin; KSP-6: 6-item Karolinska Scales of Personality; LiTMUS: Lithium Treatment-Moderate dose Use Study; mTORC1: mammalian target of rapamycin complex 1; NMDA: N-methyl-D-aspartate; PC: Principal component; PCA: Principal component analysis; PHQ-9: 9-item Patient Health Questionnaire; RIPA: Radioimmunoprecipitation assay; SD: Standard deviation; SDS: Sodium dodecyl sulfate; p70S6K: 70 ribosomal S6 kinase; UMAP: Uniform manifold approximation and projection; 4EBP1: 4E-binding protein 1.

AUTHOR CONTRIBUTIONS

K.B.: Study concept, data acquisition, data management, manuscript revision; N.O.: Protein isolation, Western blot experiments, data acquisition; A.K.: Data interpretation, co-writing first draft of the manuscript, revision of manuscript; A.A.: Statistical analysis, co-writing first draft of the manuscript, revision of the manuscript; J.B.: Study concept, plan of analysis, literature review, manuscript write-up and revisions.

ACKNOWLEDGMENTS

We thank Alexander Medenhall, PhD for arranging the collaboration, and Ayush Sharma and Alessandro Bitto, PhD for Western blot analyses.

CONFLICTS OF INTEREST

All authors declare no conflicts of interest.

ETHICAL STATEMENT AND CONSENT

The retrospective case review is exempt from Institutional Review Board approval under Category 2 of the Basic Health and Human Services Policy for Protection of Human Research Subjects Subpart A Section 46.101. All participants gave informed consent for the study by signing an informed consent form.

FUNDING

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES


1. Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, et al. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). *Pharmacogenomics J*. 2014; 14:182–91. <https://doi.org/10.1038/tpj.2013.16> PMID:23670706
2. Damiano RF, Loureiro JC, Pais MV, Pereira RF, Corradi MM, Di Santi T, Bezerra GAM, Radanovic M, Talib LL, Forlenza OV. Revisiting global cognitive and functional state 13 years after a clinical trial of lithium for mild cognitive impairment. *Braz J Psychiatry*. 2023; 45:46–9. <https://doi.org/10.47626/1516-4446-2022-2767> PMID:36049127
3. Castillo-Quan JI, Li L, Kinghorn KJ, Ivanov DK, Tain LS, Slack C, Kerr F, Nespital T, Thornton J, Hardy J, Bjedov I, Partridge L. Lithium Promotes Longevity through GSK3/NRF2-Dependent Hormesis. *Cell Rep*. 2016; 15:638–50. <https://doi.org/10.1016/j.celrep.2016.03.041> PMID:27068460
4. Castillo-Quan JI, Tain LS, Kinghorn KJ, Li L, Grönke S, Hinze Y, Blackwell TK, Bjedov I, Partridge L. A triple drug combination targeting components of the nutrient-sensing network maximizes longevity. *Proc Natl Acad Sci USA*. 2019; 116:20817–9. <https://doi.org/10.1073/pnas.1913212116> PMID:31570569
5. Sharma A, Tajerian M, Berner J. Rapamycin Augmentation of Chronic Ketamine as a Novel Treatment for Complex Regional Pain Syndrome. *Cureus*. 2023; 15:e43715. <https://doi.org/10.7759/cureus.43715> PMID:37724220
6. Abdallah CG, Averill LA, Gueorguieva R, Goktas S, Purohit P, Ranganathan M, Sherif M, Ahn KH, D'Souza DC, Formica R, Southwick SM, Duman RS, Sanacora G, Krystal JH. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin. *Neuropsychopharmacology*. 2020; 45:990–7. <https://doi.org/10.1038/s41386-020-0644-9> PMID:32092760
7. Harraz MM, Tyagi R, Cortés P, Snyder SH. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitroergic Rheb degradation. *Mol Psychiatry*. 2016; 21:313–9.

- <https://doi.org/10.1038/mp.2015.211> PMID:26782056
8. Scheepstra KWF, Mizze MR, van Scheppingen J, Adelia A, Wever DD, Mason MRJ, Dubbelaar ML, Hsiao CC, Eggen BJL, Hamann J, Huitinga I. Microglia Transcriptional Profiling in Major Depressive Disorder Shows Inhibition of Cortical Gray Matter Microglia. *Biol Psychiatry*. 2023; 94:619–29.
<https://doi.org/10.1016/j.biopsych.2023.04.020>
PMID:37121366
 9. Huang Z, You X, Chen L, Du Y, Brodeur K, Jee H, Wang Q, Linder G, Darbousset R, Cunin P, Chang MH, Wactor A, Wauford BM, et al. mTORC1 links pathology in experimental models of Still's disease and macrophage activation syndrome. *Nat Commun*. 2022; 13:6915.
<https://doi.org/10.1038/s41467-022-34480-6>
PMID:36443301
 10. Ong SM, Hadadi E, Dang TM, Yeap WH, Tan CT, Ng TP, Larbi A, Wong SC. The pro-inflammatory phenotype of the human non-classical monocyte subset is attributed to senescence. *Cell Death Dis*. 2018; 9:266.
<https://doi.org/10.1038/s41419-018-0327-1>
PMID:29449647
 11. Bajenoff M. Stromal cells; the mighty Atlas of macrophages. *Global Immunotalks*. 2023.
 12. Mandrioli J, D'Amico R, Zucchi E, De Biasi S, Banchelli F, Martinelli I, Simonini C, Lo Tartaro D, Vicini R, Fini N, Gianferrari G, Pinti M, Lunetta C, et al. Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis. *Nat Commun*. 2023; 14:4970.
<https://doi.org/10.1038/s41467-023-40734-8>
PMID:37591957
 13. Willenborg S, Sanin DE, Jais A, Ding X, Ulas T, Nüchel J, Popović M, MacVicar T, Langer T, Schultze JL, Gerbaulet A, Roers A, Pearce EJ, et al. Mitochondrial metabolism coordinates stage-specific repair processes in macrophages during wound healing. *Cell Metab*. 2021; 33:2398–414.e9.
<https://doi.org/10.1016/j.cmet.2021.10.004>
PMID:34715039
 14. Wolfe F. Stop using the American College of Rheumatology criteria in the clinic. *J Rheumatol*. 2003; 30:1671–2.
PMID:12913920
 15. Washington State Legislature. Chapter 69.77 RCW: Investigational Drugs, Biological Products, and Devices In: State W, ed. 69. Olympia, WA. 2017.
 16. Clipperton-Allen AE, Zhang A, Cohen OS, Page DT. Environmental Enrichment Rescues Social Behavioral Deficits and Synaptic Abnormalities in Pten Haploinsufficient Mice. *Genes (Basel)*. 2021; 12:1366.
<https://doi.org/10.3390/genes12091366>
PMID:34573348
 17. Bellon A, Feuillet V, Cortez-Resendiz A, Mouaffak F, Kong L, Hong LE, De Godoy L, Jay TM, Hosmalin A, Krebs MO. Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia. *Mol Psychiatry*. 2022; 27:2787–802.
<https://doi.org/10.1038/s41380-022-01514-w>
PMID:35365810
 18. Meester I, Rivera-Silva GF, González-Salazar F. Immune System Sex Differences May Bridge the Gap Between Sex and Gender in Fibromyalgia. *Front Neurosci*. 2020; 13:1414.
<https://doi.org/10.3389/fnins.2019.01414>
PMID:32009888
 19. Austad SN, Bartke A. Sex Differences in Longevity and in Responses to Anti-Aging Interventions: A Mini-Review. *Gerontology*. 2015; 62:40–6.
<https://doi.org/10.1159/000381472>
PMID:25968226
 20. Chen CJ, Sgritta M, Mays J, Zhou H, Lucero R, Park J, Wang IC, Park JH, Kaipparettu BA, Stoica L, Jafar-Nejad P, Rigo F, Chin J, et al. Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency. *Nat Med*. 2019; 25:1684–90.
<https://doi.org/10.1038/s41591-019-0608-y>
PMID:31636454
 21. Nguyen PT, Dorman LC, Pan S, Vainchtein ID, Han RT, Nakao-Inoue H, Taloma SE, Barron JJ, Molofsky AB, Kheirbek MA, Molofsky AV. Microglial Remodeling of the Extracellular Matrix Promotes Synapse Plasticity. *Cell*. 2020; 182:388–403.e15.
<https://doi.org/10.1016/j.cell.2020.05.050>
PMID:32615087
 22. Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM, Su TP. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. *Psychiatry Res*. 2018; 269:207–11.
<https://doi.org/10.1016/j.psychres.2018.08.078>
PMID:30153598
 23. Menga A, Favia M, Spera I, Vegliante MC, Gissi R, De Grassi A, Laera L, Campanella A, Gerbino A, Carrà G, Canton M, Loizzi V, Pierri CL, et al. N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. *EMBO Rep*. 2021; 22:e51981.
<https://doi.org/10.15252/embr.202051981>
PMID:34260142
 24. Sasongko TH, Kademane K, Chai Soon Hou S, Jocelyn


- TX, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. *Cochrane Database Syst Rev*. 2023; 7:CD011272.
<https://doi.org/10.1002/14651858.CD011272.pub3>
PMID:[37432030](https://pubmed.ncbi.nlm.nih.gov/37432030/)
25. Lai ZW, Kelly R, Winans T, Marchena I, Shadakshari A, Yu J, Dawood M, Garcia R, Tily H, Francis L, Faraone SV, Phillips PE, Perl A. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. *Lancet*. 2018; 391:1186–96.
[https://doi.org/10.1016/S0140-6736\(18\)30485-9](https://doi.org/10.1016/S0140-6736(18)30485-9)
PMID:[29551338](https://pubmed.ncbi.nlm.nih.gov/29551338/)
 26. Kellermayer R, Chang A, Patel K. Sirolimus (Rapamycin) Induced Mucosal Healing in Anti-Tumor Necrosis Factor Refractory Pediatric Ulcerative Colitis. *JPGN Rep*. 2022; 3:e183.
<https://doi.org/10.1097/PG9.0000000000000183>
PMID:[37168909](https://pubmed.ncbi.nlm.nih.gov/37168909/)
 27. Carnevalli LS, Taylor MA, King M, Coenen-Stass AML, Hughes AM, Bell S, Proia TA, Wang Y, Ramos-Montoya A, Wali N, Carroll D, Singh M, Moschetta M, et al. Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Ky Inhibition. *Mol Cancer Ther*. 2021; 20:1080–91.
<https://doi.org/10.1158/1535-7163.MCT-20-0961>
PMID:[33785652](https://pubmed.ncbi.nlm.nih.gov/33785652/)
 28. Hu Y, Mai W, Chen L, Cao K, Zhang B, Zhang Z, Liu Y, Lou H, Duan S, Gao Z. mTOR-mediated metabolic reprogramming shapes distinct microglia functions in response to lipopolysaccharide and ATP. *Glia*. 2020; 68:1031–45.
<https://doi.org/10.1002/glia.23760> PMID:[31793691](https://pubmed.ncbi.nlm.nih.gov/31793691/)
 29. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001; 16:606–13.
<https://doi.org/10.1046/j.1525-1497.2001.016009606.x> PMID:[11556941](https://pubmed.ncbi.nlm.nih.gov/11556941/)
 30. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006; 166:1092–7.
<https://doi.org/10.1001/archinte.166.10.1092>
PMID:[16717171](https://pubmed.ncbi.nlm.nih.gov/16717171/)
 31. Allison C, Auyeung B, Baron-Cohen S. Toward brief “Red Flags” for autism screening: The Short Autism Spectrum Quotient and the Short Quantitative Checklist for Autism in toddlers in 1,000 cases and 3,000 controls [corrected]. *J Am Acad Child Adolesc Psychiatry*. 2012; 51:202–12.e7.
<https://doi.org/10.1016/j.jaac.2011.11.003>
PMID:[22265366](https://pubmed.ncbi.nlm.nih.gov/22265366/)
 32. Gardner A, Boles RG. Symptoms of somatization as a rapid screening tool for mitochondrial dysfunction in depression. *Biopsychosoc Med*. 2008; 2:7.
<https://doi.org/10.1186/1751-0759-2-7>
PMID:[18294386](https://pubmed.ncbi.nlm.nih.gov/18294386/)
 33. Office for Human Research Protections. Subpart A of 45 CFR Part 46: basic policy for protection of human subjects. (Rockville, MD: US Department of Health and Human Services,). 2018.
 34. Hastie T, Tibshirani R, Friedman J. *The Elements of Statistical Learning: Data Mining, Inference, and Prediction*: Springer). 2008.
 35. Breiman L. Random forests. *Mach Learn*. 2001; 45:5–32.
<https://doi.org/10.1023/A:1010933404324>

SUPPLEMENTARY MATERIALS

Supplementary Figures



Supplementary Figure 1. Western blots to assay phosphorylated p70S6K/total p70S6K ratio. Western blot of p70S6K, phosphorylated p70S6K, and actin to assay the phosphorylated p70S6K/total p70S6K ratio. The actin quantity could not be estimated for the 10 samples in the bottom panel, limiting actin as control for aliquot sizing to 17 patients. Each number refers to a patient. p70S6K, p70 ribosomal S6 kinase; p-p70S6K, phosphorylated p70S6K.



Supplementary Figure 2. PCA analysis on the entire dataset. Each dot represents a patient. Dimension 1 (Dim1) explains 36.5% of the variance and dimension 2 (Dim2) explains 18% of the variance. “Label” indicates the ketamine response. AQ10, 10-item Autism Spectrum Quotient; BMI, body mass index; GAD7, 7-item Generalized Anxiety Disorder; KSP6, HC, head circumference; HC BMI, ratio head circumference/BMI ratio; Karolinska Scales of Personality; PCA, principal component analysis; Pupil Dist, pupil distance; P.P70, phosphorylated p70S6K; P.P70.P70, ratio of phosphorylated p70S6K/total p70S6K; WC, waist circumference; WC Height, ratio waist circumference/height.

Supplementary Tables

Supplementary Table 1. Clinical parameters and corresponding AUC values for ketamine response prediction.

Clinical parameter	AUC (95% CI)
Phosphorylated p70S6K	0.80 (0.53–0.97)
Ratio phosphorylated p70S6K/total p70S6K	0.78 (0.59–0.94)
Weight	0.76 (0.54–0.93)
Head circumference	0.74 (0.50–0.93)
Pupil Distance	0.74 (0.50–0.93)
Waist circumference	0.74 (0.48–0.93)
AQ-10 score	0.73 (0.51–0.91)
BMI	0.72 (0.52–0.91)
Ratio head circumference/BMI	0.72 (0.48–0.90)
GAD-7 score	0.67 (0.47–0.91)
Height	0.66 (0.48–0.91)
Ratio waist circumference/height	0.64 (0.45–0.91)
KSP-6 score	0.61 (0.45–0.90)
Age	0.58 (0.42–0.90)
p70S6K expression	0.51 (0.41–0.90)

AUC, area under the curve; AQ-10, 10-item Autism Spectrum Quotient; BMI, body mass index; CI, confidence interval; GAD-7, 7-item Generalized Anxiety Disorder; KSP-6, Karolinska Scales of Personality.

Supplementary Table 2. Ranking of clinical parameters based on random forest modelling.

Clinical parameter	Mean decrease accuracy
Phosphorylated p70S6K	0.034579
Height	0.011966
Ratio head circumference/BMI	0.010941
AQ-10 score	0.00569
BMI	0.003914
GAD-7 score	0.002192
Head circumference	0.001602
Weight	0.001418
Pupil distance	-0.00026
Ratio waist circumference/height	-0.00054
Age	-0.00058
Ratio Phosphorylated p70S6K/total p70S6K	-0.00087
p70S6K expression	-0.00336
KSP-6 score	-0.00511
Waist circumference	-0.00824

Supplementary Data

Informed consent form

RAPAMYCIN RIGHT-TO-TRY

RAPAMYCIN FOR PREVENTION AGE-RELATED PSYCHIATRIC DECLINE RIGHT TO TRY IN WASHINGTON STATE CONSENT FORM

1/17/21

“Section 1: The legislature finds that the process for approval of investigational drugs, biological products, and devices in the United States protects future patients from premature, ineffective and unsafe medications and treatments over time, but the process often takes many years. Patients who have a terminal illness do not have the luxury of waiting until an investigational drug, biological product or device receives final approval from the United States food and drug administration. The legislature further finds that patients who have a terminal illness should be to pursue the preservation of their own lives....”

1. _____ I agree that I have a serious or immediately life threatening disease (reasonable likelihood of death within 6 months OR premature death is likely without treatment)
2. _____ I understand that I have failed a reasonable subset of established treatments for my illness and/or unwilling to pursue high risk heroic treatments
3. _____ I understand that there are no major therapeutic advances available in the pipeline in terms of local clinical trials.
4. _____ I understand in the WORST CASE rapamycin could produce immunosuppression, damage to the lining of the mouth and stomach, worsen underlying diabetes, or fluid leak in the lungs or limbs. Many of these conditions could produce premature death. There may also be side effects of this drug that have not yet been discovered.
5. _____ I understand in the BEST CASE rapamycin may slow the expected progression of my illness with age. There is additional animal and human data suggesting the potential for recovery of function across a wide variety of illnesses. Your individual probability of response cannot be estimated with current technology.
6. _____ I understand that my insurance carrier may not be liable for treatment costs or any harm caused by rapamycin